Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021
Vir Biotechnology, Inc. (Nasdaq: VIR) will release its corporate update and financial results for Q1 2021, ending March 31, 2021, on May 6, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) will release its corporate update and financial results for Q1 2021, ending March 31, 2021, on May 6, 2021. The update will be available through a press release after market close on the company's website. Vir Biotechnology focuses on treating serious infectious diseases through innovative immunological technologies, developing candidates targeting COVID-19, hepatitis B, influenza A, and HIV.
Details
News Market Reaction – VIR
The recorded move for VIR in the trading session of this news was -1.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, April 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2021 on Thursday, May 6, 2021.
The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.
Contact:
Cara Miller
VP, Corporate Communications
cmiller@vir.bio
+1 415 941 6746
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.